###begin article-title 0
A Novel Function of the Receptor for Advanced Glycation End-Products (RAGE) in Association with Tumorigenesis and Tumor Differentiation of HCC
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 282 290 <span type="species:ncbi:9606">patients</span>
The expression of the receptor for advanced glycation end products (RAGE) has an impact on the mechanisms giving rise to characteristic features of various cancer cells. The purpose of this study was to elucidate the clinicopathological relevance of the level of RAGE expression in patients with hepatocellular carcinoma (HCC) and to explore the effect of RAGE expression on the characteristic features of HCC.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 280 288 <span type="species:ncbi:9606">patients</span>
The expression of RAGE was assessed in paired cancer and noncancerous tissues with HCC, using reverse-transcription polymerase chain reaction (RT-PCR), and immunohistochemistry. The quantitative RT-PCR data were analyzed in association with the clinicopathological factors of the patients with HCC. In in vitro experiments, the survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells was compared under hypoxic conditions. In addition, after reducing RAGE levels in RAGE-transfected Cos7 cells by siRNA, similar experiments were performed.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
The expression of RAGE mRNA was lower in normal liver than in hepatitis and highest in HCC. Furthermore, in HCC, it was high in well- and moderately differentiated tumors but declined as tumors dedifferentiated to poorly differentiated HCC. Furthermore, HCC lines resistant to hypoxia were found to have higher levels of RAGE expression, and RAGE transfectant also showed significantly prolonged survival under hypoxia.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
Our results suggest that HCC during the early stage of tumorigenesis with less blood supply may acquire resistance to stringent hypoxic milieu by hypoxia-induced RAGE expression.
###end p 8
###begin title 9
Keywords
###end title 9
###begin p 10
Although many cancers arise from chronic inflammation, the relationships between carcinogenesis, cancer promotion, and its molecular characteristics remain poorly understood. Hepatocellular carcinoma (HCC), which typifies an inflammation-related tumor, is one of the most common malignancies in the world, especially in Asia and Africa. Japan has a high incidence of chronic viral hepatitis, cirrhosis, and HCC. The resolution of inflammatory activity at the molecular level may correlate with prevention of hepatocarcinogenesis and cancer promotion.
###end p 10
###begin p 11
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 411 412 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 434 435 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 541 542 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 693 694 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 826 827 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 828 829 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1113 1114 1106 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1286 1287 1279 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1301 1303 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1304 1306 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1331 1333 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1352 1354 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1375 1377 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1473 1475 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1990 1992 1983 1985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 2079 2081 2072 2074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 2267 2269 2260 2262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
The receptor for advanced glycation end-products (RAGE) is a multiligand receptor classified as an immunoglobulin superfamily cell surface molecule and acts as a counter-receptor for high-mobility group box 1 (HMGB1),1 advanced glycation end-products (AGEs), S100/calgranulins, and amyloid-beta peptides. These interactions trigger the activation of key cell signaling pathways (e.g., p38 and p44/42 MAP kinase,2 NF-kappaB, cdc42/rac,3 and the generation of reactive oxygen species, and result in the production of proinflammatory cytokines.5 RAGE-mediated proinflammatory processes are now considered to contribute to the progression of many chronic diseases, such as neuropathy, nephropathy,6 macrovascular disease, amyloidoses, inflammatory conditions (e.g., rheumatoid arthritis and inflammatory bowel disease) and sepsis.5,7 In addition to RAGE-mediated proinflammatory events, recent studies have revealed that the interaction of RAGE and its ligands and the resultant signaling play a causative role in the characteristic modulation of cancer cell functions, i.e., increasing tumor invasion and metastasis.8 Furthermore, several clinical studies have demonstrated the (strong) association of RAGE expression with the malignant potential of various cancers such as gastric cancer,9 colon cancer,10,11 common bile duct cancer,12 pancreatic cancer,13 and prostate cancer,14 although one report showed a reverse correlation between RAGE expression and tumor progression.15 Thus, RAGE expression may be expected play have a significant role in the development of HCC, although no data have been reported for this tumor. In terms of HCC, it is known that the pathophysiological conditions or circumstances surrounding tumorigenesis are quite different from those reported for other cancers. For example, small HCC tumors at an early stage are continuously exposed to low oxygen and high glucose as well as the noncancerous hepatic tissues with cirrhosis in which tissue derangement occurs.15 In addition, RAGE is the receptor for AGEs produced from excessive glucose metabolism,16 extracellular HMGB1 released from necrotic cells which could be induced by hypoxia and inflammation, and serum amyloid A (SAA) produced in response to the proinflammatory cytokine IL-6,17 and these RAGE ligands are possibly generated and/or released from inflamed hepatic tissues. Our central hypothesis is thus that RAGE expression may play a particular role in tumorigenesis of HCC, in addition to the role in the invasive and/or metastatic potential of cancer cells. With this background, the objectives of this study were: (1) to clarify the relationship between RAGE expression and the clinico-pathological features of HCC and (2) to investigate the functional role of RAGE expression in HCC development.
###end p 11
###begin title 12
MATERIAL AND METHODS
###end title 12
###begin title 13
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human samples
###end title 13
###begin p 14
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1316 1317 1316 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2056 2064 2056 2064 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE&#160;1.</label>
###xml 2064 2086 2064 2086 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="15">Background of patients</p>
###xml 2064 2086 2064 2086 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="15">Background of patients</p></caption>
###xml 2086 2092 2086 2092 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Gender</th>
###xml 2086 2092 2086 2092 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Gender</th></tr>
###xml 2086 2092 2086 2092 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" colspan="2">Gender</th></tr></thead>
###xml 2092 2098 2092 2098 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Male</td>
###xml 2098 2106 2098 2106 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30 (83%)</td>
###xml 2092 2106 2092 2106 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Male</td><td align="left">30 (83%)</td></tr>
###xml 2106 2114 2106 2114 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Female</td>
###xml 2114 2121 2114 2121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6 (17%)</td>
###xml 2106 2121 2106 2121 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Female</td><td align="left">6 (17%)</td></tr>
###xml 2121 2129 2121 2129 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean age</td>
###xml 2129 2139 2129 2139 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">67.2 years</td>
###xml 2121 2139 2121 2139 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mean age</td><td align="left">67.2 years</td></tr>
###xml 2139 2149 2139 2149 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Virus type</td>
###xml 2139 2149 2139 2149 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Virus type</td></tr>
###xml 2149 2152 2149 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;B</td>
###xml 2152 2161 2152 2161 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (19.4%)</td>
###xml 2149 2161 2149 2161 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;B</td><td align="left">7 (19.4%)</td></tr>
###xml 2161 2164 2161 2164 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;C</td>
###xml 2164 2174 2164 2174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">21 (58.3%)</td>
###xml 2161 2174 2161 2174 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;C</td><td align="left">21 (58.3%)</td></tr>
###xml 2174 2180 2174 2180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;None</td>
###xml 2180 2189 2180 2189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8 (22.2%)</td>
###xml 2174 2189 2174 2189 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;None</td><td align="left">8 (22.2%)</td></tr>
###xml 2189 2209 2189 2209 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Background of livers</td>
###xml 2189 2209 2189 2209 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Background of livers</td></tr>
###xml 2209 2228 2209 2228 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Chronic hepatitis</td>
###xml 2228 2238 2228 2238 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">24 (60.7%)</td>
###xml 2209 2238 2209 2238 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Chronic hepatitis</td><td align="left">24 (60.7%)</td></tr>
###xml 2238 2255 2238 2255 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Liver cirrhosis</td>
###xml 2255 2264 2255 2264 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (11.1%)</td>
###xml 2238 2264 2238 2264 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Liver cirrhosis</td><td align="left">4 (11.1%)</td></tr>
###xml 2264 2278 2264 2278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Normal liver</td>
###xml 2278 2287 2278 2287 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8 (22.2%)</td>
###xml 2264 2287 2264 2287 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Normal liver</td><td align="left">8 (22.2%)</td></tr>
###xml 2287 2305 2287 2305 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Mean tumor size </td>
###xml 2305 2311 2305 2311 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">49.7mm</td>
###xml 2287 2311 2287 2311 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Mean tumor size </td><td align="left">49.7mm</td></tr>
###xml 2311 2329 2311 2329 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Histological grade</td>
###xml 2311 2329 2311 2329 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Histological grade</td></tr>
###xml 2329 2350 2329 2350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Well differentiated</td>
###xml 2350 2359 2350 2359 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (11.1%)</td>
###xml 2329 2359 2329 2359 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Well differentiated</td><td align="left">4 (11.1%)</td></tr>
###xml 2359 2386 2359 2386 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Moderately differentiated</td>
###xml 2386 2396 2386 2396 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">28 (77.8%)</td>
###xml 2359 2396 2359 2396 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Moderately differentiated</td><td align="left">28 (77.8%)</td></tr>
###xml 2396 2419 2396 2419 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Poorly differentiated</td>
###xml 2419 2428 2419 2428 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (11.1%)</td>
###xml 2396 2428 2396 2428 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Poorly differentiated</td><td align="left">4 (11.1%)</td></tr>
###xml 2092 2428 2092 2428 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">&#160;&#160;Male</td><td align="left">30 (83%)</td></tr><tr><td align="left">&#160;&#160;Female</td><td align="left">6 (17%)</td></tr><tr><td align="left">Mean age</td><td align="left">67.2 years</td></tr><tr><td align="left" colspan="2">Virus type</td></tr><tr><td align="left">&#160;&#160;B</td><td align="left">7 (19.4%)</td></tr><tr><td align="left">&#160;&#160;C</td><td align="left">21 (58.3%)</td></tr><tr><td align="left">&#160;&#160;None</td><td align="left">8 (22.2%)</td></tr><tr><td align="left" colspan="2">Background of livers</td></tr><tr><td align="left">&#160;&#160;Chronic hepatitis</td><td align="left">24 (60.7%)</td></tr><tr><td align="left">&#160;&#160;Liver cirrhosis</td><td align="left">4 (11.1%)</td></tr><tr><td align="left">&#160;&#160;Normal liver</td><td align="left">8 (22.2%)</td></tr><tr><td align="left">&#160;&#160;Mean tumor size </td><td align="left">49.7mm</td></tr><tr><td align="left" colspan="2">Histological grade</td></tr><tr><td align="left">&#160;&#160;Well differentiated</td><td align="left">4 (11.1%)</td></tr><tr><td align="left">&#160;&#160;Moderately differentiated</td><td align="left">28 (77.8%)</td></tr><tr><td align="left">&#160;&#160;Poorly differentiated</td><td align="left">4 (11.1%)</td></tr></tbody>
###xml 2086 2428 2086 2428 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Gender</th></tr></thead><tbody><tr><td align="left">&#160;&#160;Male</td><td align="left">30 (83%)</td></tr><tr><td align="left">&#160;&#160;Female</td><td align="left">6 (17%)</td></tr><tr><td align="left">Mean age</td><td align="left">67.2 years</td></tr><tr><td align="left" colspan="2">Virus type</td></tr><tr><td align="left">&#160;&#160;B</td><td align="left">7 (19.4%)</td></tr><tr><td align="left">&#160;&#160;C</td><td align="left">21 (58.3%)</td></tr><tr><td align="left">&#160;&#160;None</td><td align="left">8 (22.2%)</td></tr><tr><td align="left" colspan="2">Background of livers</td></tr><tr><td align="left">&#160;&#160;Chronic hepatitis</td><td align="left">24 (60.7%)</td></tr><tr><td align="left">&#160;&#160;Liver cirrhosis</td><td align="left">4 (11.1%)</td></tr><tr><td align="left">&#160;&#160;Normal liver</td><td align="left">8 (22.2%)</td></tr><tr><td align="left">&#160;&#160;Mean tumor size </td><td align="left">49.7mm</td></tr><tr><td align="left" colspan="2">Histological grade</td></tr><tr><td align="left">&#160;&#160;Well differentiated</td><td align="left">4 (11.1%)</td></tr><tr><td align="left">&#160;&#160;Moderately differentiated</td><td align="left">28 (77.8%)</td></tr><tr><td align="left">&#160;&#160;Poorly differentiated</td><td align="left">4 (11.1%)</td></tr></tbody></table>
###xml 2428 2470 2428 2470 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">Postoperative tumor recurrence 11 (30.6%).</p>
###xml 2428 2470 2428 2470 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">Postoperative tumor recurrence 11 (30.6%).</p></table-wrap-foot>
###xml 2056 2470 2056 2470 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>TABLE&#160;1.</label><caption><p textid="15">Background of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Gender</th></tr></thead><tbody><tr><td align="left">&#160;&#160;Male</td><td align="left">30 (83%)</td></tr><tr><td align="left">&#160;&#160;Female</td><td align="left">6 (17%)</td></tr><tr><td align="left">Mean age</td><td align="left">67.2 years</td></tr><tr><td align="left" colspan="2">Virus type</td></tr><tr><td align="left">&#160;&#160;B</td><td align="left">7 (19.4%)</td></tr><tr><td align="left">&#160;&#160;C</td><td align="left">21 (58.3%)</td></tr><tr><td align="left">&#160;&#160;None</td><td align="left">8 (22.2%)</td></tr><tr><td align="left" colspan="2">Background of livers</td></tr><tr><td align="left">&#160;&#160;Chronic hepatitis</td><td align="left">24 (60.7%)</td></tr><tr><td align="left">&#160;&#160;Liver cirrhosis</td><td align="left">4 (11.1%)</td></tr><tr><td align="left">&#160;&#160;Normal liver</td><td align="left">8 (22.2%)</td></tr><tr><td align="left">&#160;&#160;Mean tumor size </td><td align="left">49.7mm</td></tr><tr><td align="left" colspan="2">Histological grade</td></tr><tr><td align="left">&#160;&#160;Well differentiated</td><td align="left">4 (11.1%)</td></tr><tr><td align="left">&#160;&#160;Moderately differentiated</td><td align="left">28 (77.8%)</td></tr><tr><td align="left">&#160;&#160;Poorly differentiated</td><td align="left">4 (11.1%)</td></tr></tbody></table><table-wrap-foot><p textid="16">Postoperative tumor recurrence 11 (30.6%).</p></table-wrap-foot></table-wrap>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 511 514 <span type="species:ncbi:9606">men</span>
###xml 521 526 <span type="species:ncbi:9606">women</span>
###xml 592 600 <span type="species:ncbi:9606">patients</span>
###xml 704 721 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
###xml 1292 1300 <span type="species:ncbi:9606">patients</span>
###xml 1806 1814 <span type="species:ncbi:9606">patients</span>
###xml 2021 2028 <span type="species:ncbi:9606">patient</span>
From March 2000 to September 2005, 65 patients with primary HCC were treated surgically in the Department of Surgical Oncology and Digestive Surgery, Kagoshima University School of Medicine. Of these 65 patients, 12 who had diabetes mellitus and 6 who underwent preoperative therapy were excluded from the study. RAGE expression for Diabetes patients upregulates at various tissues.18,19,20 A further 11 patients were excluded because their RNA samples were degraded. Samples from the remaining 36 patients (30 men and 6 women with a mean age of 67.1 years) were included in the study. Seven patients (19.4%) were positive for hepatitis B surface antigen and 21 (58.3%) were positive for the antibody to hepatitis C virus. Eight patients (22.2%) were negative for both of these viruses. Twenty-four patients had chronic hepatitis and four had liver cirrhosis. The mean tumor size was 49.7 mm (range, 16-150 mm). The histological grade of each tumor was determined according to the general rules for the clinical and pathological study of primary liver cancer (The Liver Cancer Study Group of Japan, 2000).21 Four tumors (11.1%) were well-differentiated HCC, 28 (77.8%) moderately differentiated HCC, and 4 (11.1%) poorly differentiated HCC. Postoperative tumor recurrence was observed for 11 patients (30.6%) (Table 1). For immunohistochemical study, a further 12 HCC samples (six well- and six poorly differentiated HCC), obtained surgically during the same period at JA Kagoshima Kouseiren Hospital, were added and used to verify the correlation of RAGE expression with tumor differentiation. Finally, a total of 48 HCC nodules (10 well-differentiated HCC, 28 moderately differentiated HCC, and 10 poorly differentiated HCC) were studied. As a control study, six normal liver samples were collected from patients with benign or metastatic liver tumors. Written informed consent, recognized by the ethical committees of Kagoshima University School of Medicine and JA Kagoshima Kouseiren Hospital, was obtained from each patient before tissue acquisition. TABLE 1.Background of patientsGender  Male30 (83%)  Female6 (17%)Mean age67.2 yearsVirus type  B7 (19.4%)  C21 (58.3%)  None8 (22.2%)Background of livers  Chronic hepatitis24 (60.7%)  Liver cirrhosis4 (11.1%)  Normal liver8 (22.2%)  Mean tumor size 49.7mmHistological grade  Well differentiated4 (11.1%)  Moderately differentiated28 (77.8%)  Poorly differentiated4 (11.1%)Postoperative tumor recurrence 11 (30.6%).
###end p 14
###begin p 15
###xml 14 22 <span type="species:ncbi:9606">patients</span>
Background of patients
###end p 15
###begin p 16
Postoperative tumor recurrence 11 (30.6%).
###end p 16
###begin title 17
Immunohistochemistry
###end title 17
###begin p 18
###xml 246 247 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 248 249 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 352 357 <span type="species:ncbi:9796">horse</span>
Consecutive 4-mum sections were cut from each paraffin-embedding block. Sections were immunostained by anti-RAGE antibody (Santa-Cruz, CA, USA) according to the conventional immunoperoxidase technique. Briefly, after peroxidase blocking with 3% H2O2/methanol for 10 min, specimens were blocked with phosphate buffered saline (PBS) containing 5% normal horse serum (Vector Laboratories, Inc., Burlingame, CA, USA). Anti-RAGE antibody was used at 1/200. After overnight incubation at 4degreesC with the primary antibody, specimens were briefly washed in PBS and incubated at room temperature with the secondary antibody conjugated with peroxidase. The specimens were then washed in PBS and color-developed by diaminobenzidine solution (DAKO). After washing with water, specimens were counterstained with Meyer's hematoxylin (Sigma Chemical Co., St Louis, MO, USA). Immunostaining of all cases was performed at one time to ensure the same conditions of antibody reaction and DAB exposure. A total of 48 HCC nodules (10 well-differentiated HCC, 28 moderately differentiated HCC, and 10 poorly differentiated HCC) were studied. To evaluate the immunohistochemical staining, ten fields were selected and expression in 1000 tumor cells (100 cell/fields) was evaluated with high-power (x200) microscopy. The immunohistochemical expression of RAGE was defined as positive if distinct staining of the cell membrane was observed in at least 10% of tumor cells.
###end p 18
###begin title 19
Cell and cell culture
###end title 19
###begin p 20
###xml 877 878 876 877 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 632 636 <span type="species:ncbi:9913">Calf</span>
Hepatoma cell lines HepG2, HuH7, HT17, and Li7 were kindly provided by the Cell Resource Center for Biomedical Research Institute of Development, Aging, and Cancer, Tohoku University and Hep3B was obtained from the European Collection of Cell Cultures. HepG2, Hep3B, and HT17 were cultured with Dulbecco's Modified Eagle's Medium (DMEM) (1000 mg/l) and HuH7 and Li7 were cultured with RPMI. RAGE-transfected Cos7 and its mock-transfectant were kindly provided by Drs. Yamamoto, Department of Biochemistry and Molecular Vascular Biology, Kanazawa University. These transfectants were maintained with DMEM supplemented with 10% Fetal Calf Serum (FCS) in the presence of 650 mug/ml G418. A hypoxic environment was created by placing a cell culture dish with one pouch of Anaero Pack into an airtight jar. (Mitsubishi Gas Chemical Co., Inc., Tokyo, Japan). This created nearly 0% O2 conditions.
###end p 20
###begin title 21
Gene silencing of RAGE with specific siRNA
###end title 21
###begin p 22
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 198 200 198 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">TM</sup>
Cells were seeded in 12-well plates at a density of 1 x 105 cells per well and allowed to adhere overnight. Then siRNAs for the target gene or its control oligoribonucleotide mixed with Dharma FECT2TM transfection reagent (Dharmacon Inc. Chicago, USA) was added to the cells and incubated for 48h at 37degreesC The efficacy of gene silencing was evaluated using immunoblot analysis.
###end p 22
###begin title 23
MTT assay
###end title 23
###begin p 24
Cell viability was monitored after incubation for 24, 36, and 48 hours by MTT assay. Briefly, 0.5 mg/mL 3-[4,5]-2,5-diphenyltetrazolium bromide (MTT) in fresh medium was added to each well and the cells were incubated for an additional 3 hours. Afterwards, the blue formazan crystals were dissolved in 1 mL isopropanol and measured spectrophotometrically at 570 nm.
###end p 24
###begin title 25
Immunoblot analysis
###end title 25
###begin p 26
###xml 934 938 <span type="species:ncbi:9925">goat</span>
Whole cell lysates were prepared as per the Santa Cruz protocol. One milliliter of Radio-Immunoprecipitation Assay (RIPA) buffer was added to a 100 mm cell culture plate. The plates were gently rocked for 15 min at 4degreesC. Adherent cells were scrpaed with a cell scraper, followed by incubation for 30-60 min on ice. The cell lysate was microcentrifuged at 10,000g for 10 min at 4degreesC. The supernatant fluid was the total cell lysate. The supernatant was transferred to a new microfuge tube and the pellet was discarded. Twelve microgram lysates were subjected to immunoblot analysis using a 12.5% sodium dodecyl sulfate (SDS) -polyacrylamide gel followed by electrotransfer onto nitrocellulose filters. The filters were immunoreacted with anti-RAGE antibody (a gift from TORAY Research Institute, Sagamihara, Japan) or with anti-HMGB1 antibody (BD Biosciences, Tokyo, Japan) and then incubated with peroxidase-conjugated anti-goat IgG (Medical and Biological Laboratories, Nagoya, Japan). The immune complex was visualized using the Enhanced Chemiluminescence (ECL) Western blot detection system (PIERCE, Rockford, IL, USA). The amount of B-actin as an internal control was also examined using a specific antibody (Cytoskelton Inc., Denver, CO, USA and Santa Cruz, CA, USA). At least three independent experiments were performed.
###end p 26
###begin title 27
Quantitative RT-PCR
###end title 27
###begin p 28
###xml 945 946 943 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1981 1982 1916 1917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 2015 2016 1950 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
For reverse-transcription PCR (RT-PCR) and real-time quantitative PCR, total RNA was extracted from 30 mg frozen tissue using Total RNA Mini (VIOGENE, CA, USA). For cDNA synthesis, the RNA samples (1 mug) were converted into cDNA by reverse transcription (RT) using random primers (TAKARA, Siga, Japan) according to the manufacturer's instructions. To estimate the mRNA expression levels of several genes quantitatively, polymerase chain reaction (PCR) amplification was performed using a Light-Cycler system (Roche, Mannheim, Germany) and the Light-Cycler Fast Start DNA Master SYBER green I kit (Roche). Primers were as follows: RAGE: 5'-AAA CAT CAC AGC CCG GAT TG-3' and 5'-TCC GGC CTG TGT TCA GTT TC-3', HMGB1: 5'-GCT CAG AGA GGT GGA AGA CCA-3' and 5'-GGT GCA TTG GGA TCC TTG AA-3' (14) , GAPDH: 5'-TTG GTA TCG TGG AAG GAC TCA-3' and 5'-TGT CAT CAT ATT TGG CAG GTT T-3'. Amplification was carried out in 20 muL reactions containing 4 mM MgCl2, 2 muL of primer, 2 muL of Light-Cycler-FastStart DNA Master SYBR green I reagent, and 2 muL of cDNA. Reaction conditions were an initial incubation at 95degreesC for 10 min, followed by 50 cycles at 95degreesC for 10 s for denaturation, 64degreesC for 10 s for annealing of the RAGE primers, 54degreesC for 10 s for annealing of the HMGB1 primers and 60degreesC for 10 s for annealing of the GAPDH primers and 72degreesC for 10 s for extension. Melting curves were obtained according to the protocol under the following conditions: 0 s denaturation period at 95degreesC, starting temperature of 65degreesC, end temperatures of 95degreesC, and rate of temperatures increase of 0.1degreesC/s. The quantitative value of the target gene (RAGE mRNA) in each sample was normalized using GAPDH expression as an internal control. The quantitative RT-PCR assay was carried out twice and the mean value was calculated. Finally, the mRNA expression ratio of cancerous (C) to noncancerous (N) tissues was calculated using the following formula: R=log{target gene (C)/GAPDH (C)}, R=log{target gene (N)/GAPDH (N)}. These experiments were carried out twice to confirm reproducibility.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 282 283 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 416 417 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 444 445 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 541 544 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 544 546 542 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 554 555 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistical analysis was performed using the JMP IN version 5.1.2 software system (SAS institute Inc., Cary, NC, USA). Each value of mRNA expression was log transformed before statistical analysis. Gene expression was compared among normal liver, hepatitis, and HCC using Student's t-test. The relationships between RAGE-, HMGB1-mRNA expression levels and clinicopathological features were evaluated using Student's t-test and the Mann-Whitney U test, as appropriate. Immunohistochemical study of RAGE in HCC tissues was evaluated using the chi2 test. A p value of less than 0.05 was considered to be statistically significant.
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
RAGE and HMGB1 expression in normal liver, hepatitis, and HCC
###end title 32
###begin p 33
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 329 336 329 336 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;1.</label>
###xml 336 516 336 516 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">(a) RAGE expression by Western blotting (A) and RT-PCR (B). (b) HMGB1 expression by Western blotting (A) and RT-PCR (B). Abbreviations: normal, normal liver; CH, chronic hepatitis.</p>
###xml 336 516 336 516 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">(a) RAGE expression by Western blotting (A) and RT-PCR (B). (b) HMGB1 expression by Western blotting (A) and RT-PCR (B). Abbreviations: normal, normal liver; CH, chronic hepatitis.</p></caption>
###xml 516 516 516 516 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig1_HTML" id="MO1"/>
###xml 329 516 329 516 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>FIG.&#160;1.</label><caption><p textid="34">(a) RAGE expression by Western blotting (A) and RT-PCR (B). (b) HMGB1 expression by Western blotting (A) and RT-PCR (B). Abbreviations: normal, normal liver; CH, chronic hepatitis.</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig1_HTML" id="MO1"/></fig>
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
RAGE antibody yielded a strong band compared to control mouse lung extracts. Using Western blotting and RT-PCR, protein and mRNA expression of RAGE and HMGB1 were examined in both cancer and noncancerous tissues from three cases (Fig. 1a, b). All 3 cases showed co-expression of RAGE and HMGB1 protein and mRNA in these tissues. FIG. 1.(a) RAGE expression by Western blotting (A) and RT-PCR (B). (b) HMGB1 expression by Western blotting (A) and RT-PCR (B). Abbreviations: normal, normal liver; CH, chronic hepatitis.
###end p 33
###begin p 34
(a) RAGE expression by Western blotting (A) and RT-PCR (B). (b) HMGB1 expression by Western blotting (A) and RT-PCR (B). Abbreviations: normal, normal liver; CH, chronic hepatitis.
###end p 34
###begin title 35
Quantitative RAGE mRNA expression in HCC and noncancerous lesions
###end title 35
###begin p 36
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 489 496 489 496 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;2.</label>
###xml 655 656 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 702 703 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 496 710 496 710 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">(a) Quantitative RAGE mRNA expression in paired cancerous (HCC) and noncancerous tissues from 36 cases. (b) Quantitative RAGE mRNA expression in normal liver (<italic>n</italic>&#160;=&#160;6) and noncancerous and cancerous tissues (<italic>n</italic>&#160;=&#160;36).</p>
###xml 496 710 496 710 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">(a) Quantitative RAGE mRNA expression in paired cancerous (HCC) and noncancerous tissues from 36 cases. (b) Quantitative RAGE mRNA expression in normal liver (<italic>n</italic>&#160;=&#160;6) and noncancerous and cancerous tissues (<italic>n</italic>&#160;=&#160;36).</p></caption>
###xml 710 710 710 710 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig2_HTML" id="MO2"/>
###xml 489 710 489 710 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>FIG.&#160;2.</label><caption><p textid="37">(a) Quantitative RAGE mRNA expression in paired cancerous (HCC) and noncancerous tissues from 36 cases. (b) Quantitative RAGE mRNA expression in normal liver (<italic>n</italic>&#160;=&#160;6) and noncancerous and cancerous tissues (<italic>n</italic>&#160;=&#160;36).</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig2_HTML" id="MO2"/></fig>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
Comparing the quantitative expression of RAGE mRNA in paired cancer and noncancerous tissues (i.e., chronic hepatitis or liver cirrhosis) of 36 cases, HCC tissues showed significantly higher expression than noncancerous tissues (p < 0.01, Fig. 2a). Moreover, the mean values of RAGE mRNA expression in cancer and noncancerous tissues were higher (p < 0.01 and p = 0.08) than that in normal liver tissues (i.e., non-inflamed liver from benign or metastatic liver tumor patients) (Fig. 2b). FIG. 2.(a) Quantitative RAGE mRNA expression in paired cancerous (HCC) and noncancerous tissues from 36 cases. (b) Quantitative RAGE mRNA expression in normal liver (n = 6) and noncancerous and cancerous tissues (n = 36).
###end p 36
###begin p 37
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
(a) Quantitative RAGE mRNA expression in paired cancerous (HCC) and noncancerous tissues from 36 cases. (b) Quantitative RAGE mRNA expression in normal liver (n = 6) and noncancerous and cancerous tissues (n = 36).
###end p 37
###begin title 38
Relationship between RAGE mRNA expression and clinicopathological features
###end title 38
###begin p 39
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1035 1036 1035 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1164 1172 1164 1172 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE&#160;2.</label>
###xml 1172 1247 1172 1247 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Relationship between tumor RAGE expression and clinicopathological features</p>
###xml 1172 1247 1172 1247 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Relationship between tumor RAGE expression and clinicopathological features</p></caption>
###xml 1247 1254 1247 1254 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Factors</th>
###xml 1254 1280 1254 1280 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Tumor RAGE mRNA expression</th>
###xml 1280 1281 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1280 1287 1280 1287 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>p</italic> value</th>
###xml 1247 1287 1247 1287 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Factors</th><th align="left" colspan="2">Tumor RAGE mRNA expression</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr>
###xml 1287 1288 1287 1288 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n</th>
###xml 1288 1299 1288 1297 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean&#160;&#177;&#160;SD</th>
###xml 1287 1299 1287 1297 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">n</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr>
###xml 1247 1299 1247 1297 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Factors</th><th align="left" colspan="2">Tumor RAGE mRNA expression</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">n</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr></thead>
###xml 1299 1305 1297 1303 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Gender</td>
###xml 1299 1305 1297 1303 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Gender</td></tr>
###xml 1305 1311 1303 1309 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Male</td>
###xml 1311 1313 1309 1311 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 1313 1328 1311 1324 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.267&#160;&#177;&#160;0.341</td>
###xml 1328 1332 1324 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.03</td>
###xml 1305 1332 1303 1328 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Male</td><td char="." align="char">30</td><td char="&#177;" align="char">2.267&#160;&#177;&#160;0.341</td><td align="left">0.03</td></tr>
###xml 1332 1340 1328 1336 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;female</td>
###xml 1340 1341 1336 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1341 1356 1337 1350 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.777&#160;&#177;&#160;0.619</td>
###xml 1356 1356 1350 1350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1332 1356 1328 1350 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;female</td><td char="." align="char">6</td><td char="&#177;" align="char">2.777&#160;&#177;&#160;0.619</td><td align="left"/></tr>
###xml 1356 1359 1350 1353 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Age</td>
###xml 1356 1359 1350 1353 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Age</td></tr>
###xml 1359 1372 1353 1364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#8805;65 years</td>
###xml 1372 1374 1364 1366 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 1374 1389 1366 1379 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.468&#160;&#177;&#160;0.568</td>
###xml 1389 1393 1379 1383 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.03</td>
###xml 1359 1393 1353 1383 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#8805;65 years</td><td char="." align="char">26</td><td char="&#177;" align="char">2.468&#160;&#177;&#160;0.568</td><td align="left">0.03</td></tr>
###xml 1393 1404 1383 1394 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&lt;65 years</td>
###xml 1404 1406 1394 1396 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1406 1421 1396 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.052&#160;&#177;&#160;0.638</td>
###xml 1421 1421 1409 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1393 1421 1383 1409 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&lt;65 years</td><td char="." align="char">10</td><td char="&#177;" align="char">2.052&#160;&#177;&#160;0.638</td><td align="left"/></tr>
###xml 1421 1436 1409 1424 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Tumor size (mm)</td>
###xml 1421 1436 1409 1424 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Tumor size (mm)</td></tr>
###xml 1436 1443 1424 1429 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#8805;30</td>
###xml 1443 1445 1429 1431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1445 1460 1431 1444 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.395&#160;&#177;&#160;0.613</td>
###xml 1460 1464 1444 1448 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.39</td>
###xml 1436 1464 1424 1448 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#8805;30</td><td char="." align="char">11</td><td char="&#177;" align="char">2.395&#160;&#177;&#160;0.613</td><td align="left">0.39</td></tr>
###xml 1464 1469 1448 1453 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&lt;30</td>
###xml 1469 1471 1453 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 1471 1486 1455 1468 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.333&#160;&#177;&#160;0.620</td>
###xml 1486 1486 1468 1468 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1464 1486 1448 1468 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&lt;30</td><td char="." align="char">25</td><td char="&#177;" align="char">2.333&#160;&#177;&#160;0.620</td><td align="left"/></tr>
###xml 1486 1501 1468 1483 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Portal invasion</td>
###xml 1486 1501 1468 1483 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Portal invasion</td></tr>
###xml 1501 1509 1483 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Absent</td>
###xml 1509 1511 1491 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 1511 1526 1493 1506 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.358&#160;&#177;&#160;0.655</td>
###xml 1526 1530 1506 1510 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.52</td>
###xml 1501 1530 1483 1510 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Absent</td><td char="." align="char">22</td><td char="&#177;" align="char">2.358&#160;&#177;&#160;0.655</td><td align="left">0.52</td></tr>
###xml 1530 1539 1510 1519 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Present</td>
###xml 1539 1541 1519 1521 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14</td>
###xml 1541 1556 1521 1534 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.348&#160;&#177;&#160;0.594</td>
###xml 1556 1556 1534 1534 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1530 1556 1510 1534 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Present</td><td char="." align="char">14</td><td char="&#177;" align="char">2.348&#160;&#177;&#160;0.594</td><td align="left"/></tr>
###xml 1556 1571 1534 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Venous invasion</td>
###xml 1556 1571 1534 1549 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Venous invasion</td></tr>
###xml 1571 1579 1549 1557 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Absent</td>
###xml 1579 1581 1557 1559 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 1581 1596 1559 1572 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.339&#160;&#177;&#160;0.577</td>
###xml 1596 1600 1572 1576 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.47</td>
###xml 1571 1600 1549 1576 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Absent</td><td char="." align="char">26</td><td char="&#177;" align="char">2.339&#160;&#177;&#160;0.577</td><td align="left">0.47</td></tr>
###xml 1600 1609 1576 1585 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Present</td>
###xml 1609 1611 1585 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1611 1626 1587 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.357&#160;&#177;&#160;0.633</td>
###xml 1626 1626 1600 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1600 1626 1576 1600 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Present</td><td char="." align="char">10</td><td char="&#177;" align="char">2.357&#160;&#177;&#160;0.633</td><td align="left"/></tr>
###xml 1626 1643 1600 1617 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Vascular invasion</td>
###xml 1626 1643 1600 1617 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Vascular invasion</td></tr>
###xml 1643 1651 1617 1625 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Absent</td>
###xml 1651 1653 1625 1627 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19</td>
###xml 1653 1668 1627 1640 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.362&#160;&#177;&#160;0.633</td>
###xml 1668 1672 1640 1644 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.46</td>
###xml 1643 1672 1617 1644 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Absent</td><td char="." align="char">19</td><td char="&#177;" align="char">2.362&#160;&#177;&#160;0.633</td><td align="left">0.46</td></tr>
###xml 1672 1681 1644 1653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Present</td>
###xml 1681 1683 1653 1655 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1683 1698 1655 1668 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.340&#160;&#177;&#160;0.601</td>
###xml 1698 1698 1668 1668 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1672 1698 1644 1668 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Present</td><td char="." align="char">17</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.601</td><td align="left"/></tr>
###xml 1698 1721 1668 1691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Intrahepatic metastasis</td>
###xml 1698 1721 1668 1691 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Intrahepatic metastasis</td></tr>
###xml 1721 1729 1691 1699 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Absent</td>
###xml 1729 1731 1699 1701 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27</td>
###xml 1731 1746 1701 1714 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.378&#160;&#177;&#160;0.662</td>
###xml 1746 1750 1714 1718 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.33</td>
###xml 1721 1750 1691 1718 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Absent</td><td char="." align="char">27</td><td char="&#177;" align="char">2.378&#160;&#177;&#160;0.662</td><td align="left">0.33</td></tr>
###xml 1750 1759 1718 1727 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Present</td>
###xml 1759 1760 1727 1728 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1760 1775 1728 1741 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.273&#160;&#177;&#160;0.435</td>
###xml 1775 1775 1741 1741 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1750 1775 1718 1741 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Present</td><td char="." align="char">9</td><td char="&#177;" align="char">2.273&#160;&#177;&#160;0.435</td><td align="left"/></tr>
###xml 1775 1795 1741 1761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Gross classification</td>
###xml 1775 1795 1741 1761 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Gross classification</td></tr>
###xml 1795 1811 1761 1777 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Localized type</td>
###xml 1811 1813 1777 1779 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1813 1828 1779 1792 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.448&#160;&#177;&#160;0.636</td>
###xml 1828 1832 1792 1796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.13</td>
###xml 1795 1832 1761 1796 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Localized type</td><td char="." align="char">21</td><td char="&#177;" align="char">2.448&#160;&#177;&#160;0.636</td><td align="left">0.13</td></tr>
###xml 1832 1847 1796 1811 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Invasive type</td>
###xml 1847 1849 1811 1813 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 1849 1864 1813 1826 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.217&#160;&#177;&#160;0.564</td>
###xml 1864 1864 1826 1826 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1832 1864 1796 1826 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Invasive type</td><td char="." align="char">15</td><td char="&#177;" align="char">2.217&#160;&#177;&#160;0.564</td><td align="left"/></tr>
###xml 1864 1879 1826 1841 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Differentiation</td>
###xml 1864 1879 1826 1841 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Differentiation</td></tr>
###xml 1879 1885 1841 1847 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Well</td>
###xml 1885 1886 1847 1848 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1886 1901 1848 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.365&#160;&#177;&#160;0.566</td>
###xml 1901 1901 1861 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1879 1901 1841 1861 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Well</td><td char="." align="char">4</td><td char="&#177;" align="char">2.365&#160;&#177;&#160;0.566</td><td align="left"/></tr>
###xml 1901 1901 1861 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1901 1901 1861 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1901 1901 1861 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char"/>
###xml 1901 1905 1861 1865 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.43</td>
###xml 1901 1905 1861 1865 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.43</td></tr>
###xml 1905 1917 1865 1877 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Moderately</td>
###xml 1917 1919 1877 1879 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28</td>
###xml 1919 1934 1879 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.420&#160;&#177;&#160;0.580</td>
###xml 1934 1934 1892 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1905 1934 1865 1892 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Moderately</td><td char="." align="char">28</td><td char="&#177;" align="char">2.420&#160;&#177;&#160;0.580</td><td align="left"/></tr>
###xml 1934 1934 1892 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1934 1934 1892 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1934 1934 1892 1892 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char"/>
###xml 1934 1938 1892 1896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.08</td>
###xml 1934 1938 1892 1896 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.08</td></tr>
###xml 1938 1946 1896 1904 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Poorly</td>
###xml 1946 1947 1904 1905 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1947 1962 1905 1918 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.860&#160;&#177;&#160;0.783</td>
###xml 1962 1962 1918 1918 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1938 1962 1896 1918 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Poorly</td><td char="." align="char">4</td><td char="&#177;" align="char">1.860&#160;&#177;&#160;0.783</td><td align="left"/></tr>
###xml 1962 1967 1918 1923 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Stage</td>
###xml 1962 1967 1918 1923 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Stage</td></tr>
###xml 1967 1973 1923 1929 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;I,II</td>
###xml 1973 1975 1929 1931 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 1975 1990 1931 1944 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.367&#160;&#177;&#160;0.643</td>
###xml 1990 1994 1944 1948 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.55</td>
###xml 1967 1994 1923 1948 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;I,II</td><td char="." align="char">16</td><td char="&#177;" align="char">2.367&#160;&#177;&#160;0.643</td><td align="left">0.55</td></tr>
###xml 1994 2002 1948 1956 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;III,IV</td>
###xml 2002 2004 1956 1958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 2004 2019 1958 1971 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.340&#160;&#177;&#160;0.597</td>
###xml 2019 2019 1971 1971 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1994 2019 1948 1971 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;III,IV</td><td char="." align="char">20</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.597</td><td align="left"/></tr>
###xml 2019 2038 1971 1978 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">PIVKA&#8225;U</td>
###xml 2019 2038 1971 1978 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">PIVKA&#8225;U</td></tr>
###xml 2038 2046 1978 1986 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Normal</td>
###xml 2046 2047 1986 1987 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 2047 2062 1987 2000 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.704&#160;&#177;&#160;0.385</td>
###xml 2062 2062 2000 2000 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2038 2062 1978 2000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Normal</td><td char="." align="char">9</td><td char="&#177;" align="char">2.704&#160;&#177;&#160;0.385</td><td align="left"/></tr>
###xml 2062 2068 2000 2006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;High</td>
###xml 2068 2070 2006 2008 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 2070 2085 2008 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.186&#160;&#177;&#160;0.630</td>
###xml 2085 2089 2021 2025 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.03</td>
###xml 2062 2089 2000 2025 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;High</td><td char="." align="char">25</td><td char="&#177;" align="char">2.186&#160;&#177;&#160;0.630</td><td align="left">0.03</td></tr>
###xml 2089 2092 2025 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">AFP</td>
###xml 2089 2092 2025 2028 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">AFP</td></tr>
###xml 2092 2100 2028 2036 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Normal</td>
###xml 2100 2102 2036 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2102 2117 2038 2051 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.557&#160;&#177;&#160;0.586</td>
###xml 2117 2121 2051 2055 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.16</td>
###xml 2092 2121 2028 2055 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Normal</td><td char="." align="char">12</td><td char="&#177;" align="char">2.557&#160;&#177;&#160;0.586</td><td align="left">0.16</td></tr>
###xml 2121 2127 2055 2061 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;High</td>
###xml 2127 2129 2061 2063 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 2129 2144 2063 2076 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.250&#160;&#177;&#160;0.607</td>
###xml 2144 2144 2076 2076 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2121 2144 2055 2076 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;High</td><td char="." align="char">24</td><td char="&#177;" align="char">2.250&#160;&#177;&#160;0.607</td><td align="left"/></tr>
###xml 2144 2149 2076 2081 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Virus</td>
###xml 2144 2149 2076 2081 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Virus</td></tr>
###xml 2149 2152 2081 2084 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;B</td>
###xml 2152 2153 2084 2085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7</td>
###xml 2153 2168 2085 2098 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.237&#160;&#177;&#160;0.606</td>
###xml 2168 2168 2098 2098 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2149 2168 2081 2098 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;B</td><td char="." align="char">7</td><td char="&#177;" align="char">2.237&#160;&#177;&#160;0.606</td><td align="left"/></tr>
###xml 2168 2171 2098 2101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;C</td>
###xml 2171 2173 2101 2103 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 2173 2188 2103 2116 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.382&#160;&#177;&#160;0.569</td>
###xml 2188 2188 2116 2116 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2168 2188 2098 2116 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;C</td><td char="." align="char">21</td><td char="&#177;" align="char">2.382&#160;&#177;&#160;0.569</td><td align="left"/></tr>
###xml 2188 2194 2116 2122 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;None</td>
###xml 2194 2195 2122 2123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 2195 2210 2123 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.374&#160;&#177;&#160;0.779</td>
###xml 2210 2210 2136 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2188 2210 2116 2136 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;None</td><td char="." align="char">8</td><td char="&#177;" align="char">2.374&#160;&#177;&#160;0.779</td><td align="left"/></tr>
###xml 2210 2220 2136 2146 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Recurrence</td>
###xml 2210 2220 2136 2146 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Recurrence</td></tr>
###xml 2220 2228 2146 2154 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Absent</td>
###xml 2228 2230 2154 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 2230 2245 2156 2169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.485&#160;&#177;&#160;0.628</td>
###xml 2245 2249 2169 2173 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.04</td>
###xml 2220 2249 2146 2173 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Absent</td><td char="." align="char">25</td><td char="&#177;" align="char">2.485&#160;&#177;&#160;0.628</td><td align="left">0.04</td></tr>
###xml 2249 2258 2173 2182 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;Present</td>
###xml 2258 2260 2182 2184 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2260 2275 2184 2197 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">2.050&#160;&#177;&#160;0.456</td>
###xml 2275 2275 2197 2197 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 2249 2275 2173 2197 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;Present</td><td char="." align="char">11</td><td char="&#177;" align="char">2.050&#160;&#177;&#160;0.456</td><td align="left"/></tr>
###xml 1299 2275 1297 2197 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" colspan="4">Gender</td></tr><tr><td align="left">&#160;&#160;Male</td><td char="." align="char">30</td><td char="&#177;" align="char">2.267&#160;&#177;&#160;0.341</td><td align="left">0.03</td></tr><tr><td align="left">&#160;&#160;female</td><td char="." align="char">6</td><td char="&#177;" align="char">2.777&#160;&#177;&#160;0.619</td><td align="left"/></tr><tr><td align="left" colspan="4">Age</td></tr><tr><td align="left">&#160;&#160;&#8805;65 years</td><td char="." align="char">26</td><td char="&#177;" align="char">2.468&#160;&#177;&#160;0.568</td><td align="left">0.03</td></tr><tr><td align="left">&#160;&#160;&lt;65 years</td><td char="." align="char">10</td><td char="&#177;" align="char">2.052&#160;&#177;&#160;0.638</td><td align="left"/></tr><tr><td align="left" colspan="4">Tumor size (mm)</td></tr><tr><td align="left">&#160;&#160;&#8805;30</td><td char="." align="char">11</td><td char="&#177;" align="char">2.395&#160;&#177;&#160;0.613</td><td align="left">0.39</td></tr><tr><td align="left">&#160;&#160;&lt;30</td><td char="." align="char">25</td><td char="&#177;" align="char">2.333&#160;&#177;&#160;0.620</td><td align="left"/></tr><tr><td align="left" colspan="4">Portal invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">22</td><td char="&#177;" align="char">2.358&#160;&#177;&#160;0.655</td><td align="left">0.52</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">14</td><td char="&#177;" align="char">2.348&#160;&#177;&#160;0.594</td><td align="left"/></tr><tr><td align="left" colspan="4">Venous invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">26</td><td char="&#177;" align="char">2.339&#160;&#177;&#160;0.577</td><td align="left">0.47</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">10</td><td char="&#177;" align="char">2.357&#160;&#177;&#160;0.633</td><td align="left"/></tr><tr><td align="left" colspan="4">Vascular invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">19</td><td char="&#177;" align="char">2.362&#160;&#177;&#160;0.633</td><td align="left">0.46</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">17</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.601</td><td align="left"/></tr><tr><td align="left" colspan="4">Intrahepatic metastasis</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">27</td><td char="&#177;" align="char">2.378&#160;&#177;&#160;0.662</td><td align="left">0.33</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">9</td><td char="&#177;" align="char">2.273&#160;&#177;&#160;0.435</td><td align="left"/></tr><tr><td align="left" colspan="4">Gross classification</td></tr><tr><td align="left">&#160;&#160;Localized type</td><td char="." align="char">21</td><td char="&#177;" align="char">2.448&#160;&#177;&#160;0.636</td><td align="left">0.13</td></tr><tr><td align="left">&#160;&#160;Invasive type</td><td char="." align="char">15</td><td char="&#177;" align="char">2.217&#160;&#177;&#160;0.564</td><td align="left"/></tr><tr><td align="left" colspan="4">Differentiation</td></tr><tr><td align="left">&#160;&#160;Well</td><td char="." align="char">4</td><td char="&#177;" align="char">2.365&#160;&#177;&#160;0.566</td><td align="left"/></tr><tr><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.43</td></tr><tr><td align="left">&#160;&#160;Moderately</td><td char="." align="char">28</td><td char="&#177;" align="char">2.420&#160;&#177;&#160;0.580</td><td align="left"/></tr><tr><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.08</td></tr><tr><td align="left">&#160;&#160;Poorly</td><td char="." align="char">4</td><td char="&#177;" align="char">1.860&#160;&#177;&#160;0.783</td><td align="left"/></tr><tr><td align="left" colspan="4">Stage</td></tr><tr><td align="left">&#160;&#160;I,II</td><td char="." align="char">16</td><td char="&#177;" align="char">2.367&#160;&#177;&#160;0.643</td><td align="left">0.55</td></tr><tr><td align="left">&#160;&#160;III,IV</td><td char="." align="char">20</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.597</td><td align="left"/></tr><tr><td align="left" colspan="4">PIVKA&#8225;U</td></tr><tr><td align="left">&#160;&#160;Normal</td><td char="." align="char">9</td><td char="&#177;" align="char">2.704&#160;&#177;&#160;0.385</td><td align="left"/></tr><tr><td align="left">&#160;&#160;High</td><td char="." align="char">25</td><td char="&#177;" align="char">2.186&#160;&#177;&#160;0.630</td><td align="left">0.03</td></tr><tr><td align="left" colspan="4">AFP</td></tr><tr><td align="left">&#160;&#160;Normal</td><td char="." align="char">12</td><td char="&#177;" align="char">2.557&#160;&#177;&#160;0.586</td><td align="left">0.16</td></tr><tr><td align="left">&#160;&#160;High</td><td char="." align="char">24</td><td char="&#177;" align="char">2.250&#160;&#177;&#160;0.607</td><td align="left"/></tr><tr><td align="left" colspan="4">Virus</td></tr><tr><td align="left">&#160;&#160;B</td><td char="." align="char">7</td><td char="&#177;" align="char">2.237&#160;&#177;&#160;0.606</td><td align="left"/></tr><tr><td align="left">&#160;&#160;C</td><td char="." align="char">21</td><td char="&#177;" align="char">2.382&#160;&#177;&#160;0.569</td><td align="left"/></tr><tr><td align="left">&#160;&#160;None</td><td char="." align="char">8</td><td char="&#177;" align="char">2.374&#160;&#177;&#160;0.779</td><td align="left"/></tr><tr><td align="left" colspan="4">Recurrence</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">25</td><td char="&#177;" align="char">2.485&#160;&#177;&#160;0.628</td><td align="left">0.04</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">11</td><td char="&#177;" align="char">2.050&#160;&#177;&#160;0.456</td><td align="left"/></tr></tbody>
###xml 1247 2275 1247 2197 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Factors</th><th align="left" colspan="2">Tumor RAGE mRNA expression</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">n</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr></thead><tbody><tr><td align="left" colspan="4">Gender</td></tr><tr><td align="left">&#160;&#160;Male</td><td char="." align="char">30</td><td char="&#177;" align="char">2.267&#160;&#177;&#160;0.341</td><td align="left">0.03</td></tr><tr><td align="left">&#160;&#160;female</td><td char="." align="char">6</td><td char="&#177;" align="char">2.777&#160;&#177;&#160;0.619</td><td align="left"/></tr><tr><td align="left" colspan="4">Age</td></tr><tr><td align="left">&#160;&#160;&#8805;65 years</td><td char="." align="char">26</td><td char="&#177;" align="char">2.468&#160;&#177;&#160;0.568</td><td align="left">0.03</td></tr><tr><td align="left">&#160;&#160;&lt;65 years</td><td char="." align="char">10</td><td char="&#177;" align="char">2.052&#160;&#177;&#160;0.638</td><td align="left"/></tr><tr><td align="left" colspan="4">Tumor size (mm)</td></tr><tr><td align="left">&#160;&#160;&#8805;30</td><td char="." align="char">11</td><td char="&#177;" align="char">2.395&#160;&#177;&#160;0.613</td><td align="left">0.39</td></tr><tr><td align="left">&#160;&#160;&lt;30</td><td char="." align="char">25</td><td char="&#177;" align="char">2.333&#160;&#177;&#160;0.620</td><td align="left"/></tr><tr><td align="left" colspan="4">Portal invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">22</td><td char="&#177;" align="char">2.358&#160;&#177;&#160;0.655</td><td align="left">0.52</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">14</td><td char="&#177;" align="char">2.348&#160;&#177;&#160;0.594</td><td align="left"/></tr><tr><td align="left" colspan="4">Venous invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">26</td><td char="&#177;" align="char">2.339&#160;&#177;&#160;0.577</td><td align="left">0.47</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">10</td><td char="&#177;" align="char">2.357&#160;&#177;&#160;0.633</td><td align="left"/></tr><tr><td align="left" colspan="4">Vascular invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">19</td><td char="&#177;" align="char">2.362&#160;&#177;&#160;0.633</td><td align="left">0.46</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">17</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.601</td><td align="left"/></tr><tr><td align="left" colspan="4">Intrahepatic metastasis</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">27</td><td char="&#177;" align="char">2.378&#160;&#177;&#160;0.662</td><td align="left">0.33</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">9</td><td char="&#177;" align="char">2.273&#160;&#177;&#160;0.435</td><td align="left"/></tr><tr><td align="left" colspan="4">Gross classification</td></tr><tr><td align="left">&#160;&#160;Localized type</td><td char="." align="char">21</td><td char="&#177;" align="char">2.448&#160;&#177;&#160;0.636</td><td align="left">0.13</td></tr><tr><td align="left">&#160;&#160;Invasive type</td><td char="." align="char">15</td><td char="&#177;" align="char">2.217&#160;&#177;&#160;0.564</td><td align="left"/></tr><tr><td align="left" colspan="4">Differentiation</td></tr><tr><td align="left">&#160;&#160;Well</td><td char="." align="char">4</td><td char="&#177;" align="char">2.365&#160;&#177;&#160;0.566</td><td align="left"/></tr><tr><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.43</td></tr><tr><td align="left">&#160;&#160;Moderately</td><td char="." align="char">28</td><td char="&#177;" align="char">2.420&#160;&#177;&#160;0.580</td><td align="left"/></tr><tr><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.08</td></tr><tr><td align="left">&#160;&#160;Poorly</td><td char="." align="char">4</td><td char="&#177;" align="char">1.860&#160;&#177;&#160;0.783</td><td align="left"/></tr><tr><td align="left" colspan="4">Stage</td></tr><tr><td align="left">&#160;&#160;I,II</td><td char="." align="char">16</td><td char="&#177;" align="char">2.367&#160;&#177;&#160;0.643</td><td align="left">0.55</td></tr><tr><td align="left">&#160;&#160;III,IV</td><td char="." align="char">20</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.597</td><td align="left"/></tr><tr><td align="left" colspan="4">PIVKA&#8225;U</td></tr><tr><td align="left">&#160;&#160;Normal</td><td char="." align="char">9</td><td char="&#177;" align="char">2.704&#160;&#177;&#160;0.385</td><td align="left"/></tr><tr><td align="left">&#160;&#160;High</td><td char="." align="char">25</td><td char="&#177;" align="char">2.186&#160;&#177;&#160;0.630</td><td align="left">0.03</td></tr><tr><td align="left" colspan="4">AFP</td></tr><tr><td align="left">&#160;&#160;Normal</td><td char="." align="char">12</td><td char="&#177;" align="char">2.557&#160;&#177;&#160;0.586</td><td align="left">0.16</td></tr><tr><td align="left">&#160;&#160;High</td><td char="." align="char">24</td><td char="&#177;" align="char">2.250&#160;&#177;&#160;0.607</td><td align="left"/></tr><tr><td align="left" colspan="4">Virus</td></tr><tr><td align="left">&#160;&#160;B</td><td char="." align="char">7</td><td char="&#177;" align="char">2.237&#160;&#177;&#160;0.606</td><td align="left"/></tr><tr><td align="left">&#160;&#160;C</td><td char="." align="char">21</td><td char="&#177;" align="char">2.382&#160;&#177;&#160;0.569</td><td align="left"/></tr><tr><td align="left">&#160;&#160;None</td><td char="." align="char">8</td><td char="&#177;" align="char">2.374&#160;&#177;&#160;0.779</td><td align="left"/></tr><tr><td align="left" colspan="4">Recurrence</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">25</td><td char="&#177;" align="char">2.485&#160;&#177;&#160;0.628</td><td align="left">0.04</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">11</td><td char="&#177;" align="char">2.050&#160;&#177;&#160;0.456</td><td align="left"/></tr></tbody></table>
###xml 1164 2275 1164 2197 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>TABLE&#160;2.</label><caption><p textid="40">Relationship between tumor RAGE expression and clinicopathological features</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Factors</th><th align="left" colspan="2">Tumor RAGE mRNA expression</th><th align="left" rowspan="2"><italic>p</italic> value</th></tr><tr><th align="left">n</th><th align="left">Mean&#160;&#177;&#160;SD</th></tr></thead><tbody><tr><td align="left" colspan="4">Gender</td></tr><tr><td align="left">&#160;&#160;Male</td><td char="." align="char">30</td><td char="&#177;" align="char">2.267&#160;&#177;&#160;0.341</td><td align="left">0.03</td></tr><tr><td align="left">&#160;&#160;female</td><td char="." align="char">6</td><td char="&#177;" align="char">2.777&#160;&#177;&#160;0.619</td><td align="left"/></tr><tr><td align="left" colspan="4">Age</td></tr><tr><td align="left">&#160;&#160;&#8805;65 years</td><td char="." align="char">26</td><td char="&#177;" align="char">2.468&#160;&#177;&#160;0.568</td><td align="left">0.03</td></tr><tr><td align="left">&#160;&#160;&lt;65 years</td><td char="." align="char">10</td><td char="&#177;" align="char">2.052&#160;&#177;&#160;0.638</td><td align="left"/></tr><tr><td align="left" colspan="4">Tumor size (mm)</td></tr><tr><td align="left">&#160;&#160;&#8805;30</td><td char="." align="char">11</td><td char="&#177;" align="char">2.395&#160;&#177;&#160;0.613</td><td align="left">0.39</td></tr><tr><td align="left">&#160;&#160;&lt;30</td><td char="." align="char">25</td><td char="&#177;" align="char">2.333&#160;&#177;&#160;0.620</td><td align="left"/></tr><tr><td align="left" colspan="4">Portal invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">22</td><td char="&#177;" align="char">2.358&#160;&#177;&#160;0.655</td><td align="left">0.52</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">14</td><td char="&#177;" align="char">2.348&#160;&#177;&#160;0.594</td><td align="left"/></tr><tr><td align="left" colspan="4">Venous invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">26</td><td char="&#177;" align="char">2.339&#160;&#177;&#160;0.577</td><td align="left">0.47</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">10</td><td char="&#177;" align="char">2.357&#160;&#177;&#160;0.633</td><td align="left"/></tr><tr><td align="left" colspan="4">Vascular invasion</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">19</td><td char="&#177;" align="char">2.362&#160;&#177;&#160;0.633</td><td align="left">0.46</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">17</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.601</td><td align="left"/></tr><tr><td align="left" colspan="4">Intrahepatic metastasis</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">27</td><td char="&#177;" align="char">2.378&#160;&#177;&#160;0.662</td><td align="left">0.33</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">9</td><td char="&#177;" align="char">2.273&#160;&#177;&#160;0.435</td><td align="left"/></tr><tr><td align="left" colspan="4">Gross classification</td></tr><tr><td align="left">&#160;&#160;Localized type</td><td char="." align="char">21</td><td char="&#177;" align="char">2.448&#160;&#177;&#160;0.636</td><td align="left">0.13</td></tr><tr><td align="left">&#160;&#160;Invasive type</td><td char="." align="char">15</td><td char="&#177;" align="char">2.217&#160;&#177;&#160;0.564</td><td align="left"/></tr><tr><td align="left" colspan="4">Differentiation</td></tr><tr><td align="left">&#160;&#160;Well</td><td char="." align="char">4</td><td char="&#177;" align="char">2.365&#160;&#177;&#160;0.566</td><td align="left"/></tr><tr><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.43</td></tr><tr><td align="left">&#160;&#160;Moderately</td><td char="." align="char">28</td><td char="&#177;" align="char">2.420&#160;&#177;&#160;0.580</td><td align="left"/></tr><tr><td align="left"/><td char="." align="char"/><td char="&#177;" align="char"/><td align="left">0.08</td></tr><tr><td align="left">&#160;&#160;Poorly</td><td char="." align="char">4</td><td char="&#177;" align="char">1.860&#160;&#177;&#160;0.783</td><td align="left"/></tr><tr><td align="left" colspan="4">Stage</td></tr><tr><td align="left">&#160;&#160;I,II</td><td char="." align="char">16</td><td char="&#177;" align="char">2.367&#160;&#177;&#160;0.643</td><td align="left">0.55</td></tr><tr><td align="left">&#160;&#160;III,IV</td><td char="." align="char">20</td><td char="&#177;" align="char">2.340&#160;&#177;&#160;0.597</td><td align="left"/></tr><tr><td align="left" colspan="4">PIVKA&#8225;U</td></tr><tr><td align="left">&#160;&#160;Normal</td><td char="." align="char">9</td><td char="&#177;" align="char">2.704&#160;&#177;&#160;0.385</td><td align="left"/></tr><tr><td align="left">&#160;&#160;High</td><td char="." align="char">25</td><td char="&#177;" align="char">2.186&#160;&#177;&#160;0.630</td><td align="left">0.03</td></tr><tr><td align="left" colspan="4">AFP</td></tr><tr><td align="left">&#160;&#160;Normal</td><td char="." align="char">12</td><td char="&#177;" align="char">2.557&#160;&#177;&#160;0.586</td><td align="left">0.16</td></tr><tr><td align="left">&#160;&#160;High</td><td char="." align="char">24</td><td char="&#177;" align="char">2.250&#160;&#177;&#160;0.607</td><td align="left"/></tr><tr><td align="left" colspan="4">Virus</td></tr><tr><td align="left">&#160;&#160;B</td><td char="." align="char">7</td><td char="&#177;" align="char">2.237&#160;&#177;&#160;0.606</td><td align="left"/></tr><tr><td align="left">&#160;&#160;C</td><td char="." align="char">21</td><td char="&#177;" align="char">2.382&#160;&#177;&#160;0.569</td><td align="left"/></tr><tr><td align="left">&#160;&#160;None</td><td char="." align="char">8</td><td char="&#177;" align="char">2.374&#160;&#177;&#160;0.779</td><td align="left"/></tr><tr><td align="left" colspan="4">Recurrence</td></tr><tr><td align="left">&#160;&#160;Absent</td><td char="." align="char">25</td><td char="&#177;" align="char">2.485&#160;&#177;&#160;0.628</td><td align="left">0.04</td></tr><tr><td align="left">&#160;&#160;Present</td><td char="." align="char">11</td><td char="&#177;" align="char">2.050&#160;&#177;&#160;0.456</td><td align="left"/></tr></tbody></table></table-wrap>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
To elucidate the biological significance of RAGE expression in HCC, we compared the levels of RAGE mRNA expression with the clinico-pathological features of 36 patients. As shown in Table 2, we noted significant differences in RAGE mRNA expression in association with gender, age, the levels of protein induced by vitamin K absence or antagonist (PIVKA-II), and postoperative recurrence. In terms of gender and age, the results are in accordance with a previous report.23 The expression levels of RAGE mRNA tended to be lower in poorly differentiated tumors compared to well- or moderately differentiated tumors (p = 0.06). Moreover, the levels of RAGE mRNA showed a negative correlation with PIVKA-II levels and the presence or absence of recurrence. There were no significant differences regarding tumor size, intrahepatic metastasis, and vascular invasion. On the other hand, it should be noted that a significant difference in the levels of RAGE expression was observed between hepatitis virus-positive and virus--egative tissues (p < 0.01) in the study of noncancerous inflammatory liver tissues (i.e., chronic hepatitis or liver cirrhosis) (data not shown). TABLE 2.Relationship between tumor RAGE expression and clinicopathological featuresFactorsTumor RAGE mRNA expressionp valuenMean +/- SDGender  Male302.267 +/- 0.3410.03  female62.777 +/- 0.619Age  >/=65 years262.468 +/- 0.5680.03  <65 years102.052 +/- 0.638Tumor size (mm)  >/=30112.395 +/- 0.6130.39  <30252.333 +/- 0.620Portal invasion  Absent222.358 +/- 0.6550.52  Present142.348 +/- 0.594Venous invasion  Absent262.339 +/- 0.5770.47  Present102.357 +/- 0.633Vascular invasion  Absent192.362 +/- 0.6330.46  Present172.340 +/- 0.601Intrahepatic metastasis  Absent272.378 +/- 0.6620.33  Present92.273 +/- 0.435Gross classification  Localized type212.448 +/- 0.6360.13  Invasive type152.217 +/- 0.564Differentiation  Well42.365 +/- 0.5660.43  Moderately282.420 +/- 0.5800.08  Poorly41.860 +/- 0.783Stage  I,II162.367 +/- 0.6430.55  III,IV202.340 +/- 0.597PIVKAdouble daggerU  Normal92.704 +/- 0.385  High252.186 +/- 0.6300.03AFP  Normal122.557 +/- 0.5860.16  High242.250 +/- 0.607Virus  B72.237 +/- 0.606  C212.382 +/- 0.569  None82.374 +/- 0.779Recurrence  Absent252.485 +/- 0.6280.04  Present112.050 +/- 0.456
###end p 39
###begin p 40
Relationship between tumor RAGE expression and clinicopathological features
###end p 40
###begin title 41
RAGE expression and tumor differentiation in HCC
###end title 41
###begin p 42
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 476 483 476 483 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;3.</label>
###xml 483 719 483 719 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">RAGE expression by immunohistochemical staining: (a) well-differentiated HCC, (b) moderately (mod.) differentiated HCC, (c) poorly differentiated HCC, (e) the number of RAGE positive or negative cases according to tumor differentiation.</p>
###xml 483 719 483 719 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43">RAGE expression by immunohistochemical staining: (a) well-differentiated HCC, (b) moderately (mod.) differentiated HCC, (c) poorly differentiated HCC, (e) the number of RAGE positive or negative cases according to tumor differentiation.</p></caption>
###xml 719 719 719 719 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig3_HTML" id="MO3"/>
###xml 476 719 476 719 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>FIG.&#160;3.</label><caption><p textid="43">RAGE expression by immunohistochemical staining: (a) well-differentiated HCC, (b) moderately (mod.) differentiated HCC, (c) poorly differentiated HCC, (e) the number of RAGE positive or negative cases according to tumor differentiation.</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig3_HTML" id="MO3"/></fig>
To verify the correlation of RAGE expression with HCC differentiation, we carried out an immunohistochemical examination. (Fig. 3a-c) Well- and moderately differentiated HCC showed a high percentage of RAGE positivity (70% and 64%, respectively); only 2 of 10 (20%) were positive in poorly differentiated HCC (Fig. 3d). Statistically, there were significant differences in the rates of positivity between well- and moderately differentiated HCC and poorly differentiated HCC. FIG. 3.RAGE expression by immunohistochemical staining: (a) well-differentiated HCC, (b) moderately (mod.) differentiated HCC, (c) poorly differentiated HCC, (e) the number of RAGE positive or negative cases according to tumor differentiation.
###end p 42
###begin p 43
RAGE expression by immunohistochemical staining: (a) well-differentiated HCC, (b) moderately (mod.) differentiated HCC, (c) poorly differentiated HCC, (e) the number of RAGE positive or negative cases according to tumor differentiation.
###end p 43
###begin title 44
RAGE expression in hepatoma cell lines
###end title 44
###begin p 45
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 652 659 652 659 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;4.</label>
###xml 659 860 659 860 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">(a) RAGE expression in hepatoma cell lines by Western blotting. (b) RAGE expression in hepatoma cell lines under hypoxic conditions by Western blotting. N, normoxic conditions; A, anaerobic conditions.</p>
###xml 659 860 659 860 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">(a) RAGE expression in hepatoma cell lines by Western blotting. (b) RAGE expression in hepatoma cell lines under hypoxic conditions by Western blotting. N, normoxic conditions; A, anaerobic conditions.</p></caption>
###xml 860 860 860 860 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig4_HTML" id="MO4"/>
###xml 652 860 652 860 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>FIG.&#160;4.</label><caption><p textid="46">(a) RAGE expression in hepatoma cell lines by Western blotting. (b) RAGE expression in hepatoma cell lines under hypoxic conditions by Western blotting. N, normoxic conditions; A, anaerobic conditions.</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig4_HTML" id="MO4"/></fig>
RAGE antibody yielded a strong band on Western blot analysis of the control RAGE transfected Cos7 cells (Fig. 4a, lane 1). In this experimental setting, the well-differentiated HCC cell line HuH7 (lane 6) expressed RAGE protein at a modest level. The poorly differentiated HCC cell line HT17 (lane 7) expressed RAGE protein at a low level. Hepatoma cell lines Hep3B and Li7 (lane 4 and 5), derived from tumors of unknown state of differentiation, expressed RAGE protein at a modest level. HepG2 (lane 3) did not express RAGE protein at all. These results were very similar to RAGE mRNA expression and depend on the pathological differentiation of HCC. FIG. 4.(a) RAGE expression in hepatoma cell lines by Western blotting. (b) RAGE expression in hepatoma cell lines under hypoxic conditions by Western blotting. N, normoxic conditions; A, anaerobic conditions.
###end p 45
###begin p 46
(a) RAGE expression in hepatoma cell lines by Western blotting. (b) RAGE expression in hepatoma cell lines under hypoxic conditions by Western blotting. N, normoxic conditions; A, anaerobic conditions.
###end p 46
###begin title 47
Enhanced RAGE expression under hypoxic conditions
###end title 47
###begin p 48
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
Early carcinogenesis occurs in an avascular environment and under conditions of hypoxia.15,23,24 In order to clarify the role of RAGE expression under hypoxic conditions, all hepatoma cell lines were cultured in an anaerobic environment. Li7 could survive for 48 h, Hep3B for 12 h, and HuH7 for 24 h under such conditions, up to the appearance of signs of cell death. HepG2 and HT17 rapidly died under anaerobic conditions. The RAGE-positive cell lines (Li7, Hep3B and HuH7) were more tolerant of anaerobic conditions than RAGE-negative or weakly expressing cell lines (HepG2 and HT17). Moreover, RAGE expression in the cell lines that survived was clearly upregulated in response to the hypoxic conditions (Fig. 4b).
###end p 48
###begin title 49
Enhancement of cell survival in anaerobic conditions following RAGE transfection
###end title 49
###begin p 50
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 400 407 400 407 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;5.</label>
###xml 407 649 407 649 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Comparison of cell survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells under anaerobic conditions. Cell survival of both groups was estimated from six dishes at each time point using the MTT assay. *p&#160;&lt;&#160;0.01 by Student&#8217;s t-test.</p>
###xml 407 649 407 649 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Comparison of cell survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells under anaerobic conditions. Cell survival of both groups was estimated from six dishes at each time point using the MTT assay. *p&#160;&lt;&#160;0.01 by Student&#8217;s t-test.</p></caption>
###xml 649 649 649 649 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig5_HTML" id="MO5"/>
###xml 400 649 400 649 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>FIG.&#160;5.</label><caption><p textid="51">Comparison of cell survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells under anaerobic conditions. Cell survival of both groups was estimated from six dishes at each time point using the MTT assay. *p&#160;&lt;&#160;0.01 by Student&#8217;s t-test.</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig5_HTML" id="MO5"/></fig>
These findings led to the hypothesis that RAGE expression could confer tolerance to hypoxia in HCC. Therefore, we investigated the survival of RAGE-transfected and mock-transfected cells under hypoxic conditions. In continuous incubation under hypoxic conditions, as expected, RAGE-transfected Cos7 cells clearly survived longer than mock-transfected Cos7 cells (observed at 36 h and 48 h) (Fig. 5). FIG. 5.Comparison of cell survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells under anaerobic conditions. Cell survival of both groups was estimated from six dishes at each time point using the MTT assay. *p < 0.01 by Student's t-test.
###end p 50
###begin p 51
Comparison of cell survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells under anaerobic conditions. Cell survival of both groups was estimated from six dishes at each time point using the MTT assay. *p < 0.01 by Student's t-test.
###end p 51
###begin title 52
Decline of cell survival in hypoxic conditions following RAGE reduced by siRNA
###end title 52
###begin p 53
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 315 322 315 322 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;6.</label>
###xml 322 540 322 540 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54">RAGE level in RAGE-transfected Cos7 cells were reduced by siRNA RAGE-transfected Cos7 cells reduced RAGE level by siRNA decreased more than the cells mixed with only transfection reagent. *p&#160;&lt;&#160;0.01 by Student&#8217;s t-test.</p>
###xml 322 540 322 540 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54">RAGE level in RAGE-transfected Cos7 cells were reduced by siRNA RAGE-transfected Cos7 cells reduced RAGE level by siRNA decreased more than the cells mixed with only transfection reagent. *p&#160;&lt;&#160;0.01 by Student&#8217;s t-test.</p></caption>
###xml 540 540 540 540 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig6_HTML" id="MO6"/>
###xml 315 540 315 540 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>FIG.&#160;6.</label><caption><p textid="54">RAGE level in RAGE-transfected Cos7 cells were reduced by siRNA RAGE-transfected Cos7 cells reduced RAGE level by siRNA decreased more than the cells mixed with only transfection reagent. *p&#160;&lt;&#160;0.01 by Student&#8217;s t-test.</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig6_HTML" id="MO6"/></fig>
Consistent with the previous result, reduction of RAGE expression with anti-RAGE siRNA re-increased susceptibility to hypoxia-induced injury in RAGE-overexpressed Cos7 transfectant (Fig. 6a,b), suggesting that RAGE expression might play an important role in the acquirement of hypoxia-resistant cellular phenotype. FIG. 6.RAGE level in RAGE-transfected Cos7 cells were reduced by siRNA RAGE-transfected Cos7 cells reduced RAGE level by siRNA decreased more than the cells mixed with only transfection reagent. *p < 0.01 by Student's t-test.
###end p 53
###begin p 54
RAGE level in RAGE-transfected Cos7 cells were reduced by siRNA RAGE-transfected Cos7 cells reduced RAGE level by siRNA decreased more than the cells mixed with only transfection reagent. *p < 0.01 by Student's t-test.
###end p 54
###begin title 55
DISCUSSION
###end title 55
###begin p 56
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
Hepatocellular carcinogenesis and associated tumorigenesis occur in a stringent and restrictive environment, such as the cirrhotic liver in which tissue oxygen supply is insufficient. Moreover, in the liver, with a dual blood supply from the hepatic artery and portal vein, liver-specific oxygen and glucose supply are available dependent upon the degree of liver disorder. The multiligand receptor RAGE is particularly relevant in this context. The ligands for RAGE may be produced abundantly during HCC development. For example, HMGB1 released from necrotic cells and AGE generated in the process of higher hepatic glucose metabolism are considered to be major candidates (i.e., the presence of HMGB1 and carboxymethyl lysine in HCC; data not shown). Hepatic SAA production in response to IL-6 may also be included.19 In addition, RAGE expression and its downstream signaling are now considered to play a significant role in the progression of various cancers as well as the development of inflammatory lesions.
###end p 56
###begin p 57
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 815 817 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 818 820 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 857 859 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
Another aspect of the biology of RAGE was suggested by the features of retinoic acid-induced neuroblastoma differentiation, in which RAGE expression played a more important role in cellular survival than in neurite outgrowth.25 In this model, inhibition of RAGE function partially blocked the increase in levels of the anti-apoptotic protein Bcl-2 in the process of neuronal differentiation,25 indicating that RAGE and its signaling also might contribute to the survival of certain cancer cell types undergoing "differentiation". Furthermore, although indirectly, our previous study demonstrated that NF-kappaB, currently considered as a causative transcriptional factor for various inflammatory events and also known as a major RAGE-mediated signal, played an important role in the survival of neuronal tumor cells26,27 and in experimentally developed HCC.28
###end p 57
###begin p 58
The present study demonstrated that increased RAGE expression was highly associated with the status of pathological "differentiation" in HCC, which played a significant role in acquisition of the hypoxia-resistant phenotype of tumor cells. This conclusion is supported by several lines of experimental evidence. First, the level of RAGE expression was higher in well- and moderately differentiated HCC, while it diminished as the tumors dedifferentiated to poorly differentiated HCC. This was consistent with the evidence that a negative correlation was observed between the level of RAGE mRNA expression and either the level of PIVKA II or the incidence of postoperative recurrence. Second, the analysis of five HCC lines revealed that three of these (Li7, Hep3B, and HuH7) that are resistant to hypoxic stress characteristically showed higher levels of RAGE expression compared to the two hypoxia-intolerant cell lines HepG2 and HT17. Third, sublethal hypoxia exposure induced significantly increased RAGE expression in hypoxia-resistant HCC lines. In the analysis of the association between the level of RAGE expression and the "differentiation status" of HCC lines, the level of RAGE expression was higher in "possibly differentiated" lines (i.e., HCC with low Alpha-Fet protein (AFP) production), consistent with the results from clinical samples. Finally, cells overexpressing RAGE exogenously showed prolonged survival under hypoxic conditions compared to control mock-transfected cells, and siRNA experiments demonstrated similar results.
###end p 58
###begin p 59
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 1095 1097 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1450 1452 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 1453 1455 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1881 1882 1881 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1883 1885 1883 1885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 2011 2013 2011 2013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 2131 2133 2131 2133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 2236 2242 2236 2242 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIG.&#160;7</label>
###xml 2242 2449 2242 2443 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="60">Scheme of the change of RAGE expression according to the sequential change of liver tissue: normal &#8594; chronic hepatitis (CH) &#8594; cirrhosis &#8594; HCC. The value indicates the quantitative RAGE mRNA expression.</p>
###xml 2242 2449 2242 2443 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="60">Scheme of the change of RAGE expression according to the sequential change of liver tissue: normal &#8594; chronic hepatitis (CH) &#8594; cirrhosis &#8594; HCC. The value indicates the quantitative RAGE mRNA expression.</p></caption>
###xml 2449 2449 2443 2443 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9698_Fig7_HTML" id="MO7"/>
###xml 2236 2449 2236 2443 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>FIG.&#160;7</label><caption><p textid="60">Scheme of the change of RAGE expression according to the sequential change of liver tissue: normal &#8594; chronic hepatitis (CH) &#8594; cirrhosis &#8594; HCC. The value indicates the quantitative RAGE mRNA expression.</p></caption><graphic position="anchor" xlink:href="10434_2007_9698_Fig7_HTML" id="MO7"/></fig>
Our conclusion also provides a new hypothetical concept that hepatic RAGE expression may be relevant to the stage or severity of inflammation and the incidence of carcinogenesis and early tumorigenesis of HCC (Fig. 7). In the process of the development of an HCC lesion, increased RAGE expression by inflamed hepatocytes may confer adaptation to an advanced hypoxic environment during remodeling and carcinogenesis with accelerated cell proliferation. In this context, an HCC lesion which is highly associated with inflammation caused by either hepatitis viruses or drugs is developed through a process of multistage carcinogenesis, i.e., from inflammatory lesions (e.g., hepatitis, cirrhosis and precancerous lesion) to adenomatous hyperplasia, and eventually into HCC. Once cancer is established, HCC dedifferentiates step-by-step to a more malignant histology, from well- and moderately to poorly differentiated HCC. It has also been pointed out that the vascular supply changes significantly between each stage of tumorigenesis. According to the evidence from several clinical studies,15,29,30 both adenomatous hyperplasia and well-differentiated HCC are hypovascular tumors primarily fed by the portal vein system, while moderately and poorly differentiated HCC are hypervascular tumors primarily fed by arterial blood. In addition, early carcinogenesis and the development of the malignant phenotype generally occur in an avascular environment.31-33 Increased RAGE expression, at least in part, may thus play an important role in the mechanism of early HCC development from precancerous inflammatory lesions. In addition, about the expression of RAGE being lower in poorly differentiated HCC when compared to well and moderately differentiated HCC, gastric and colon cancers have been showed that RAGE and other ligands interacts act on tumor promotion in clinical materials.9,11 However, prostate cancer was demonstrated to show no correlation between RAGE expression and tumor differentiation and depth.14 Moreover, non-small-cell lung cancers have been showed a reverse correlation between RAGE expression and tumor stage.34 This result is partially similar to our results. RAGE expression of each clinical samples is various. FIG. 7Scheme of the change of RAGE expression according to the sequential change of liver tissue: normal --> chronic hepatitis (CH) --> cirrhosis --> HCC. The value indicates the quantitative RAGE mRNA expression.
###end p 59
###begin p 60
Scheme of the change of RAGE expression according to the sequential change of liver tissue: normal --> chronic hepatitis (CH) --> cirrhosis --> HCC. The value indicates the quantitative RAGE mRNA expression.
###end p 60
###begin p 61
Some reports have shown that RAGE-expressed cells have invasion and migration potential. Our data from clinical samples did no' relate to the potential. In vivo, invasive and metastatic potential are reflected by many factors, which may have caused our results.
###end p 61
###begin p 62
Our results raise many questions concerning mechanistic and practical processes. It is important to know whether RAGE can bind HMGB1 secreted from activated macrophages in hepatic inflammation, or if occupancy of RAGE by inhibitors would obviate binding of the stimulatory ligands. The functional role of downstream signaling of the RAGE would also be important to determine the cytoprotective mechanism under hypoxia.
###end p 62
###begin p 63
Our findings have provided the first evidence of the clinical relevance and function of RAGE in HCC, namely differentiation-associated RAGE expression that confers a hypoxia-resistant phenotype. Although other mechanisms may also be important, our data also introduce the concept that RAGE and its functions may be possible candidates for therapeutic targets in the treatment of HCC.
###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
We thank Drs. Yasuhiko Yamamoto and Hiroshi Yamamoto (Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medicine) for kindly providing RAGE-transfectant and its control Cos-7 cells.
###end p 65
###begin p 66
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons
###end article-title 68
###begin article-title 69
Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion
###end article-title 69
###begin article-title 70
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways
###end article-title 70
###begin article-title 71
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
###end article-title 71
###begin article-title 72
###xml 51 55 <span type="species:ncbi:10090">mice</span>
HMG-1 as a late mediator of endotoxin lethality in mice
###end article-title 72
###begin article-title 73
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
###end article-title 73
###begin article-title 74
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response
###end article-title 74
###begin article-title 75
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
###end article-title 75
###begin article-title 76
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer
###end article-title 76
###begin article-title 77
Differential effects between amphoterin and advanced glycation end products on colon cancer cells
###end article-title 77
###begin article-title 78
Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer
###end article-title 78
###begin article-title 79
###xml 69 74 <span type="species:ncbi:9606">human</span>
Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells
###end article-title 79
###begin article-title 80
###xml 35 40 <span type="species:ncbi:9606">human</span>
Differential expression of RAGE in human pancreatic carcinoma cells
###end article-title 80
###begin article-title 81
Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development
###end article-title 81
###begin article-title 82
Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium
###end article-title 82
###begin article-title 83
Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease
###end article-title 83
###begin article-title 84
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
###end article-title 84
###begin article-title 85
Blockade of late stages of autoimmune diabetes by inhibition of the Receptor for Advanced Glycation End Products
###end article-title 85
###begin article-title 86
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily
###end article-title 86
###begin article-title 87
RAGE Drives the development of glomerulosclerosis and implicates Podocyte activation in the pathogenesis of diabetic nephropathy
###end article-title 87
###begin article-title 88
Morphological diagnosis of hepatocellular carcinoma: special emphasis on intranodular hemodynamic imaging
###end article-title 88
###begin article-title 89
Imaging blood flow characteristics of hepatocellular carcinoma
###end article-title 89
###begin article-title 90
Receptor for advanced end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of neuroblastoma
###end article-title 90
###begin article-title 91
The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism
###end article-title 91
###begin article-title 92
Interleukin 6 mediated differentiation and rescue of cell redox in PC12 cells exposed to ionizing radiation
###end article-title 92
###begin article-title 93
###xml 111 114 <span type="species:ncbi:10116">rat</span>
Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma
###end article-title 93
###begin article-title 94
Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study
###end article-title 94
###begin article-title 95
Benign and malignant nodules in cirrhotic livers: distinction based on blood supply
###end article-title 95
###begin article-title 96
Why do cancers have high aerobic glycolysis?
###end article-title 96
###begin article-title 97
Determination of local oxygen consumption rates in tumors
###end article-title 97
###begin article-title 98
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation
###end article-title 98
###begin article-title 99
Down-regulation of the receptor for advanced glycation end-products(RAGE) supports non-small cell lung carcinoma
###end article-title 99
###begin p 100
Grant support : Grants-in-Aid for Scientific Research from the Japan Society for the promotion of Science (no. 14370359 to SU, IM, and TA, and no.16659493 to K A).
###end p 100

